Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
by Zacks Equity Research
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
5 Low Price-to-Book Stocks to Buy in a Volatile Market
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Is Jazz Pharmaceuticals a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?
by Zacks Equity Research
Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?
by Zacks Equity Research
Workiva (WK) continues to focus on developing its flagship product, Wdesk cloud platform, which continues to gain traction.
Zillow Group (ZG) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zillow Group (ZG) to benefit from strong growth of it's Premier Agent Business. We expect the company to gain from increasing traffic at its mobile apps and websites, strong rental demand and MLS partnerships.
ANSYS (ANSS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Synergies from acquisitions are enabling ANSYS(ANSS) to bring innovative solutions to the market and also to enhance its foothold in the competitive simulations market.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.
Is a Beat in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.
5 Low Price-to-Book Stocks Worth Buying in July
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
by Zacks Equity Research
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
5 Stocks Near 52-Week High: Is More Upside in the Cards?
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels with potential to scale higher.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
5 Low-Beta Stocks to Buy as Trade Conflict Intensifies
by Swarup Gupta
Since trade tensions could drastically dent investor confidence, picking value stocks with low-beta looks like a smart option at this point.